Global Information
회사소개 | 문의 | 위시리스트

세계의 유전자 치료 시장 분석

Global & US Gene Therapy Market Forecast to 2020

리서치사 RNCOS E-Services Pvt. Ltd.
발행일 2018년 10월 상품 코드 235806
페이지 정보 영문 205 Pages
가격
US $ 2,200 ₩ 2,694,000 PDF by E-mail (Single User License)
US $ 2,800 ₩ 3,429,000 PDF by E-mail (Multi-User License)


세계의 유전자 치료 시장 분석 Global & US Gene Therapy Market Forecast to 2020
발행일 : 2018년 10월 페이지 정보 : 영문 205 Pages

세계의 유전자 치료(Gene Therapy) 시장에 대해 조사 분석했으며, 업계 동향과 촉진요인, 응용별 분석, 지역별 분석, 개발 단계별 파이프라인 분석, 주요 기업 개요 등의 정보를 전해드립니다

제1장 애널리스트의 견해

제2장 분석 방법

제3장 유전자 치료 : 서론

제4장 산업 개요

  • 시장 성장 촉진요인
    • 기존 암 치료법의 실패
    • 선진국가에서 유전자 치료 상품화에 초점
    • 만성적 질환 및 치명적 질환의 이환율 증가
    • 벤처 투자 기업의 관심 고조
  • 시장 성장 억제요인
    • 엄격한 규제와 안전성에 대한 우려
    • 최신 기술의 잠재적인 위험성
    • 고가의 유전 치료제
  • 시장 기회
    • 유럽에서의 유전 치료제 인가
    • B형 혈우병에 대한 유전자 치료가 중요한 기회를 제공
  • 산업 동향
    • 유전자 발현억제(Gene Silencing) : 약진을 이룬다
    • 최첨단 치료 : 유전자 치료와 줄기세포 기술을 조합한다
    • 면역결핍증후군 : 유전자 치료의 중심
    • 나노테크놀러지 : 유전자 치료를 활성화
    • 유전자 치료 : 실명 치료에 새로운 희망
    • 유전자 치료 : 잠재적 암 치료법으로서
  • 성공 법칙
    • R&D 활동 투자

제5장 유전자 치료의 임상시험 평가 및 파이프라인 분석

  • 임상시험
    • 지역별
    • 증상별
    • 유전자 종류별
    • 벡터별
    • 임상시험 상(相)별
  • 파이프라인 분석

제6장 규제 현황 및 상환 시나리오

  • 주요 지역별 시장
    • 미국
    • 캐나다
    • 유럽
    • 일본
    • 중국
    • 인도
    • 호주
  • 세계 시장의 상환 시나리오

제7장 출시된 유전자 치료제

  • Neovasculgen
  • Glybera
  • Gendicine, Rexin-G, Oncorine
    • Gendicine
    • Rexin G
    • Oncorine

제8장 세계의 유전자 치료 시장

제9장 응용 영역별 시장

  • 심혈관질환
  • 감염증
  • 신경질환
  • 유전자질환
  • 기타

제10장 지역별 시장 규모

  • 북미
  • 유럽
  • 아시아
  • 기타 지역

제11장 경쟁 환경

  • 각 기업이 채용하고 있는 전략
    • 전략적 협업
    • 인수
    • 자금 조달 및 투자
  • 유전자 치료에서 성장을 이룬 기업(2015년)

제12장 주요 기업 분석

  • Spark Therapeutics, LLC
  • ViroMed Co. Ltd. dba VM BioPharma
  • Advantagene Inc.
  • Bluebird Bio
  • Sanofi
  • Vical Inc.
  • Oxford BioMedica Plc
  • Genethon
  • uniQure N.V.
  • Human Stem Cells Institute
  • Shanghai Sunway Biotech Co. Ltd.
  • Sibiono GeneTech Co. Ltd.

도표

LSH 16.02.24

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Gene therapy is one of the most widely researched fields in the healthcare industry. The high potential of gene therapy to cure various chronic diseases makes it a popular research area. Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others.

According to RNCOS' new research report “Global & US Gene Therapy Market Forecast to 2020”, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up. Primarily, the gene therapy market is dominated by oncology applications, with several companies and academic institutions focusing on novel and ‘difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. Furthermore, the chapter also provides details regarding the various aspects of the clinical trials in the different gene therapy application by phases, vector types, etc.

The major part of the revenue of gene therapy market is generated from research phase. Most of the gene therapy products are in research phases, only few products have been commercialized till date. The report also provides the sales of major marketed gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms which are aiding them to develop new products. The study highlights the applications for which the investments have been received.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia, and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.

RNCOS, in its report, further covers how major trends and drivers, mainly gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understand the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

Table of Contents

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction

  • 3.1. Classification of Gene Therapy Techniques
  • 3.2. Physical Methods of Gene Transfer
    • 3.2.1. Electroporation
    • 3.2.2. Hydrodynamic
    • 3.2.3. Microinjection
    • 3.2.4. Particle Bombardment
    • 3.2.5. Ultrasound-Mediated Transfection
  • 3.3. Vectors for Gene Therapy
    • 3.3.1. Viral Vectors
      • 3.3.1.1. Adenoviral Vectors
      • 3.3.1.2. Adeno-associated Virus Vectors
      • 3.3.1.3. Retroviral Vectors
      • 3.3.1.4. Lentiviral Vectors
    • 3.3.2. Non Viral Vectors
      • 3.3.2.1. Naked DNA/Plasmid Vectors
      • 3.3.2.2. Oligonucleotides
      • 3.3.2.3. Liposomes, Lipoplexes and Polyplexes
      • 3.3.2.4. Gene-Activated Matrix

4. Industry Overview

  • 4.1. Market Drivers
    • 4.1.1. Failure of Conventional Therapies to Treat Cancers
    • 4.1.2. Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations
    • 4.1.3. Rising Incidence of Chronic and Life-Threatening Diseases
    • 4.1.4. Growing Interest of Venture Capital Firms
  • 4.2. Market Restraints
    • 4.2.1. Stringent Regulatory Laws & Safety Concerns
    • 4.2.2. Challenges in Commercialization of Gene Therapy
    • 4.2.3. High Cost of the Gene Therapy Drugs
    • 4.2.4. Pitfalls in Current Technique
    • 4.2.5. Production & Manufacturing: A Unique Challenge for Gene Therapies
  • 4.3. Market Opportunities
    • 4.3.1. Approval of Gene Therapy Drug in Europe
    • 4.3.2. Gene Therapy for Hemophilia B Offers Significant Opportunity
  • 4.4. Industry Trends
    • 4.4.1. Gene Silencing: Gaining Momentum
    • 4.4.2. Advanced Therapies: Combining Gene Therapy and Stem Cell Technology
    • 4.4.3. Immunodeficiency Syndromes: The Focus of Gene Therapy
    • 4.4.4. Nanotechnology: Empowering Gene Therapy
    • 4.4.5. Gene Therapy: A New Hope to Treat Blindness
    • 4.4.6. Gene Therapy: Potential Cure for Cancer
  • 4.5. Winning Imperatives
    • 4.5.1. Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis

  • 5.1. Clinical Trials
    • 5.1.1. By Geography
    • 5.1.2. By Indication
    • 5.1.3. By Gene Type
    • 5.1.4. By Vector
    • 5.1.5. By Clinical Trial Phase
  • 5.2. Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario

  • 6.1. Regulatory Landscape
    • 6.1.1. US
    • 6.1.2. Canada
    • 6.1.3. Europe
    • 6.1.4. Japan
    • 6.1.5. China
    • 6.1.6. India
    • 6.1.7. Australia
  • 6.2. Reimbursement Scenario in Global Market

7. Marketed Gene Therapies

  • 7.1. Neovasculgen
  • 7.2. Glybera
  • 7.3. Gendicine, Rexin-G, Oncorine
    • 7.3.1. Gendicine
    • 7.3.2. Rexin G
    • 7.3.3. Oncorine

8. Gene Therapy Market

  • 8.1. Global
  • 8.2. US

9. Gene Therapy Market by Application

  • 9.1. Oncology
    • 9.1.1. Clinical Trials
    • 9.1.2. Prevalence
    • 9.1.3. Market Outlook
  • 9.2. Cardiovascular Diseases
    • 9.2.1. Clinical Trials
    • 9.2.2. Prevalence
    • 9.2.3. Market Outlook
  • 9.3. Infectious Diseases
    • 9.3.1. Clinical Trials
    • 9.3.2. Prevalence
    • 9.3.3. Market Outlook
  • 9.4. Neurological Diseases
    • 9.4.1. Clinical Trials
    • 9.4.2. Prevalence
    • 9.4.3. Market Outlook
  • 9.5. Genetic Diseases
    • 9.5.1. Clinical Trials
    • 9.5.2. Prevalence
    • 9.5.3. Market Outlook
  • 9.6. Others
    • 9.6.1. Clinical Trials
    • 9.6.2. Prevalence
    • 9.6.3. Market Outlook

10. Gene Therapy Market Size by Geography

  • 10.1. North America
  • 10.2. Europe
  • 10.3. Asia
  • 10.4. Rest of the World (RoW)

11. Competitive Landscape

  • 11.1. Strategies Adopted by Various Players
    • 11.1.1. Strategic Collaborations
    • 11.1.2. Acquisitions
    • 11.1.3. Funding & Investments
  • 11.2. Companies Progress in Gene Therapy In 2015

12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)

  • 12.1. Spark Therapeutics, LLC
  • 12.2. ViroMed Co. Ltd. dba VM BioPharma
  • 12.3. Advantagene Inc.
  • 12.4. Bluebird Bio
  • 12.5. Sanofi
  • 12.6. Vical Inc.
  • 12.7. Oxford BioMedica Plc
  • 12.8. Genethon
  • 12.9. uniQure N.V.
  • 12.10. Human Stem Cells Institute
  • 12.11. Shanghai Sunway Biotech Co. Ltd.
  • 12.12. Sibiono GeneTech Co. Ltd.

List of Figures:

  • Figure 4-1: Global - Major Venture Capitalist Investments in Gene Therapy Product Development (Billion US$), 1999 to 2015
  • Figure 5-1: Global - Number of Approved Gene Therapy Clinical Trials (2005-2015)
  • Figure 5-2: Global - Geographical Distribution of Gene Therapy Clinical Trials by Continents (%)
  • Figure 5-3: Global - Geographical Distribution of Gene Therapy Clinical Trials by Countries (%)
  • Figure 5-4: US - Geographical Distribution of Gene Therapy Clinical Trials by States (%)
  • Figure 5-5: Global - Gene Therapy Clinical Trials by Indication (%)
  • Figure 5-6: US - Gene Therapy Clinical Trials by Indication (%)
  • Figure 5-7: Global - Gene Therapy Clinical Trials by Types of Gene Transferred (%)
  • Figure 5-8: Global - Gene Therapy Clinical Trials by Vectors (%)
  • Figure 5-9: US - Gene Therapy Clinical Trials by Vectors (%)
  • Figure 5-10: Global - Gene Therapy Clinical Trials by Phase (%)
  • Figure 5-11: US - Gene Therapy Clinical Trials by Phase (%)
  • Figure 6-1: US - Number of New Cell Therapy and Gene Therapy Products Submission to FDA (2003-2010)
  • Figure 6-2: Japan - Evaluation System of Gene Therapy Clinical Trial
  • Figure 7-1: Global - Neovasculgen Sales (Million US$), 2013 & 2014
  • Figure 8-1: Global - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 8-2: US - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-1: Global - Gene Therapy Market by Application (%), 2015
  • Figure 9-2: Global - Gene Therapy Market by Application (%), 2020
  • Figure 9-3: US - Gene Therapy Market by Application (%), 2015
  • Figure 9-4: US - Gene Therapy Market by Application (%), 2020
  • Figure 9-5: Global - Oncology Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-6: US - Oncology Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-7: Global - Oncology Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-8: US - Oncology Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-9: Global - Oncology Gene Therapy Clinical Trials by Type (%)
  • Figure 9-10: US - Oncology Gene Therapy Clinical Trials by Type (%)
  • Figure 9-11: Global - Oncology Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-13: Global - Oncology Gene Therapy Market by Geography (%), 2015
  • Figure 9-12: US - Oncology Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-14: Global - Key Cardiovascular Diseases Gene Therapy Ongoing Clinical Trials
  • Figure 9-15: US - Key Cardiovascular Diseases Gene Therapy Ongoing Clinical Trials
  • Figure 9-16: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-17: US - Cardiovascular Disease Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-18: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-19: US - Cardiovascular Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-20: Global - Cardiovascular Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-21: US - Cardiovascular Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-22: Global - Cardiovascular Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-24: Global - Cardiovascular Disease Gene Therapy Market by Geography (%), 2015
  • Figure 9-23: US - Cardiovascular Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-25: Global - Infectious Disease Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-26: US - Infectious Disease Gene Therapy Clinical Trials by Vectors (%)
  • Figure 9-27: Global - Infectious Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-28: US - Infectious Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-29: Global - Infectious Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-30: US - Infectious Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-31: Global - Infectious Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-33: Global - Infectious Disease Gene Therapy Market by Geography (%), 2015
  • Figure 9-32: US - Infectious Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-34: Global - Neurological Diseases Gene Therapy Clinical Trials by Vector (%)
  • Figure 9-35: US - Neurological Diseases Gene Therapy Clinical Trials by Vector (%)
  • Figure 9-36: Global - Neurological Diseases Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-37: US - Neurological Diseases Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-38: Global - Neurological Diseases Gene Therapy Clinical Trials by Type (%)
  • Figure 9-39: US - Neurological Diseases Gene Therapy Clinical Trials by Type (%)
  • Figure 9-40: Global - Neurological Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-42: Global - Neurological Disease Gene Therapy Market by Geography (%), 2015
  • Figure 9-41: US - Neurological Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-43: Global - Genetic Disease Gene Therapy Clinical Trials by Vector (%)
  • Figure 9-44: US - Genetic Disease Gene Therapy Clinical Trials by Vector (%)
  • Figure 9-45: Global - Genetic Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-46: US - Genetic Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-47: Global - Genetic Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-48: US - Genetic Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-49: Global - Genetic Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-50: Global - Genetic Disease Gene Therapy Market, by Geography (%), 2015
  • Figure 9-51: US - Genetic Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-52: US - Other Disease Gene Therapy Clinical Trials by Vector (%)
  • Figure 9-53: US - Other Disease Gene Therapy Clinical Trials by Phase (%)
  • Figure 9-54: Global - Other Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-55: US - Other Disease Gene Therapy Clinical Trials by Type (%)
  • Figure 9-56: Global - Other Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 9-57: Global - Other Disease Gene Therapy Market by Geography (%), 2015
  • Figure 9-58: US - Other Disease Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-1: Global - Gene Therapy Market by Geography (%), 2015
  • Figure 10-2: North America - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-3: Europe - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-4: Asia - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 10-5: Asia - Number of Gene Therapy Laboratories by Major Asian Countries (2014)
  • Figure 10-6: India - Number of Gene Therapy Laboratories (2000, 2010 & 2013)
  • Figure 10-7: Rest of the World - Gene Therapy Market (Million US$), 2014, 2015 & 2020
  • Figure 11-1: Key Growth Strategies Adopted by Key Players (2013 to 2015)
  • Figure 11-2: Key Players Focusing on Strategic Collaborations (2013 to 2015)
  • Figure 11-3: Key Players Focusing on Strategic Acquisitions (2013 to 2015)
  • Figure 11-4: Key Players Focusing on Funding & Investments (2013 to 2015)
  • Figure 11-5: Companies Progress in Gene Therapy till 2015

List of Tables:

  • Table 4-1: US - Promising Gene Therapies in Late-Stage Development
  • Table 4-2: Europe - Promising Gene Therapies in Late-Stage Development
  • Table 4-3: Gene Therapy Companies Funded by Venture Capital Firms
  • Table 4-4: Current Status of Clinical Trials for Hemophilia
  • Table 5-1: Human Gene Transfer Trials Approved by Condition
  • Table 5-2: Global - Key Gene Therapy Ongoing Clinical Trials
  • Table 5-3: US - Key Gene Therapy Ongoing Clinical Trials
  • Table 6-1: China - Key Players and their Products in Gene Therapy
  • Table 9-1: Global - Key Oncology Gene Therapy Ongoing Clinical Trials
  • Table 9-2: US - Key Oncology Gene Therapy Ongoing Clinical Trials
  • Table 9-3: Global - Oncology Incidence by Geography (‘000), 2015 & 2020
  • Table 9-4: US - Oncology Incidence (‘000), 2015 & 2020
  • Table 9-5: Global - Key Infectious Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-6: US - Key Infectious Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-7: Global - HIV Prevalence & Incidence by Geography (‘000), 2014
  • Table 9-8: Global - Key Neurological Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-9: US - Key Neurological Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-10: Global - Parkinson Disease Prevalence by Geography (Million), 2010
  • Table 9-11: US - Parkinson Disease Prevalence (Million), 2010
  • Table 9-12: Global - Key Genetic Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-13: US - Key Genetic Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-14: Global - Hemophilia Prevalence by Geography, 2010 & 2013
  • Table 9-15: US - Hemophilia Prevalence, 2010 & 2013
  • Table 9-16: Global - Key Other Disease Gene Therapy Ongoing Clinical Trials
  • Table 9-17: US - Key Other Disease Gene Therapy Ongoing Clinical Trials
  • Table 12-1: Spark Therapeutics LLC - Clinical Pipeline in Gene Therapy
  • Table 12-2: ViroMed Co. Ltd. - Clinical Pipeline in Gene Therapy
  • Table 12-3: Advantagene Inc. - Clinical Pipeline in Gene Therapy
  • Table 12-4: Bluebird Bio - Clinical Pipeline in Gene Therapy
  • Table 12-5: Sanofi - Clinical Pipeline in Gene Therapy
  • Table 12-6: Vical Inc. - Clinical Pipeline in Gene Therapy
  • Table 12-7: Oxford Biomedica Plc - Clinical Pipeline in Gene Therapy
  • Table 12-8: Genethon - Clinical Pipeline in Gene Therapy
  • Table 12-9: UniQure N.V. - Clinical Pipeline in Gene Therapy
  • Table 12-10: Human Stem Cells Institute - Clinical Pipeline in Gene Therapy
  • Table 12-11: Shanghai Sunway Biotech Co. Ltd. - Clinical Pipeline in Gene Therapy
  • Table 12-12: Sibiono GeneTech Co. Ltd. - Clinical Pipeline in Gene Therapy
Back to Top
전화 문의
F A Q